Solid Biosciences Inc., focusing on Duchenne muscular dystrophy (DMD) treatments, is advancing with SGT-003, a gene therapy candidate. With a strong financial position and innovative capsid technology, it aims to disrupt the DMD treatment landscape. Despite operating at a loss, its potential for superior efficacy and safety profiles positions it as a key player in the gene therapy market.